From controversy to clarity: reimagining the role of CDK4/6 inhibitors in the adjuvant setting– a number needed to treat perspective
Saved in:
| Main Author: | Armando Orlandi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Online Access: | https://doi.org/10.1007/s00432-025-06229-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
by: Efthymia Skafida, et al.
Published: (2023-01-01) -
Should CDK4/6 inhibitors replace chemotherapy in HR+ /HER2− metastatic breast cancer with visceral crisis? Evaluating the emerging evidence
by: Armando Orlandi
Published: (2025-06-01) -
Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01) -
Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?
by: Alexander C.J. van Akkooi, et al.
Published: (2024-12-01) -
The Effect of Proton Pump Inhibitors on Metastatic Breast Cancer in Patients Treated with CDK4/6i
by: Mohamed Khalifa, et al.
Published: (2025-04-01)